AZN: H1 2019 Results
AstraZeneca PLC
25 July 2019 07:00 BST
H1 2019 Results
Continuing strong top-line performance underpins confidence in sustainable growth
First-half Product Sales growth of 12% (17% at CER1) to $11,183m included an acceleration in second-quarter Product Sales to $5,718m (+14%, +19% at CER). The second quarter saw every sales region and all three therapy areas deliver an encouraging performance, including:
- The sustained performance of new medicines2 (+66%, +72% at CER) to $2,385m
- Sales growth by therapy area in the quarter: Oncology +51% (+57% at CER) to $2,167m, New CVRM3 +9% (+13% at CER) to $1,061m and Respiratory +2% (+7% at CER) to $1,252m
- Sales growth by region in the quarter: total Emerging Markets sales grew by 17% (27% at CER) to $1,947m, with China sales growth of 34% (44% at CER) to $1,166m, ahead of recent trends. US sales increased by 16% to $1,877m; Europe sales returned to growth, increasing by 1% (8% at CER) to $1,047m. Japan sales increased by 30% (34% at CER) to $672m
To view the announcement in full please refer the associated PDF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.